Recombinant Human Apolipoprotein M(APOM)

In Stock
Code CSB-EP001947HU
Size US$1726
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity Greater than 90% as determined by SDS-PAGE.
Target Names APOM
Uniprot No. O95445
Research Area Signal Transduction
Alternative Names Apo M; Apo-M; Apolipoprotein M; ApoM; APOM_HUMAN; G3A; HSPC336; MGC22400; NG20; NG20 like protein; Protein G3a
Species Homo sapiens (Human)
Source E.coli
Expression Region 1-188aa
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight 49.8kDa
Protein Length Full Length of Mature Protein
Tag Info N-terminal 10xHis-GST-tagged
Form Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Basically, we can dispatch the products out in 3-7 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Target Data

Function Probably involved in lipid transport. Can bind sphingosine-1-phosphate, myristic acid, palmitic acid and stearic acid, retinol, all-trans-retinoic acid and 9-cis-retinoic acid.
Gene References into Functions
  1. Obese patients showed significantly lower plasmatic ApoM levels than people with normal body weight, and ApoM level showed a strong correlation with CRP, TNF-alpha, and IL-6 levels, which indicated that ApoM might be regulated by these inflammatory factors. PMID: 30110274
  2. These results demonstrated that ApoM protein mass were clearly higher in the NSCLC tissues than in non-small cell lung cancer (NSCLC) tissues. Overexpression of ApoM could promote NSCLC cell proliferation and invasion in vitro and tumor growth in vivo, which might be via upregulating S1PR1 and activating the ERK1/2 and PI3K/AKT signaling pathways. PMID: 29750961
  3. results do not suggest a diagnostic role for ApoM plasma levels in patients with primary VTE. Moreover, the current study suggests that role of ApoM as a risk factor may differ for primary VTE and recurrent VTE in male patients. PMID: 28914078
  4. These S1P-induced enhancements in growth factors and chemotactic cytokines in retinal pigment epithelium cells were significantly inhibited by ApoM treatment. Additionally, in vivo experiments using a laser-induced choroidal neovascularization (CNV) murine model demonstrated that intravitreal ApoM injection significantly reduced the progression of CNV formation. PMID: 29301231
  5. The potential of mean force for sphingosine-1-phosphate unbinding from apoM reflected a large binding strength of more than 60 kJ/mol. This high unbinding free energy for sphingosine-1-phosphate underlines the observed specificity of the physiological effects of sphingosine-1-phosphate as it suggests that the spontaneous release of sphingosine-1-phosphate from apoM is unlikely. PMID: 27476912
  6. results demonstrated that lower APOM levels in SLE patients and correlated with disease activity. PMID: 28476116
  7. Sequenced the ApoM gene in recurrent venous thromboembolism (VTE) and identified six polymorphisms. ApoM rs805297 was significantly associated with higher risk of VTE recurrence in male but not in female patients. PMID: 27277397
  8. Single nucleotide polymorphism in ApoM gene is associated with chronic obstructive pulmonary disease. PMID: 28927745
  9. ApoM T-855C and T-778C polymorphisms were found to be associated with obesity by regulating HDL metabolism, and the T alleles of apoM T-778C were shown to be more strongly correlated. PMID: 28245483
  10. liver mRNA levels of apoM and apoA1 decreased strongly upon sepsis induction. PMID: 26990127
  11. 17beta-estradiol induced up-regulation of apoM in HepG2 cells is through an ER-alpha-dependent pathway involving ER-alpha binding element in the promoter of the apoM gene. PMID: 28359281
  12. A shift in ApoM/sphingosine 1-phosphate between HDL-particles in women with type 1 diabetes mellitus Is associated with impaired anti-inflammatory effects of the ApoM/S1P complex. PMID: 28385702
  13. ApoM-bound sphingosine-1-phosphate regulates adhesion molecule abundance, leukocyte-endothelial adhesion, and endothelial barrier function via sphingosine-1-phosphate receptor1. PMID: 27879252
  14. HDL-associated ApoM is anti-apoptotic by delivering sphingosine 1-phosphate to S1P1 and S1P3 receptors on vascular endothelium. PMID: 28179022
  15. Plasma apoM concentrations are higher in patients with hyperlipidaemia than in healthy controls. Low plasma apoM levels in patients with T2DM are likely caused by diabetes but are not induced by hyperlipidaemia. PMID: 27633510
  16. The polymorphism C-724del in the promoter region of the apoM gene could confer the risk of T2DM among eastern Han Chinese. Unfortunately, the lowing of plasma apoM levels of C-724del mutant allele carriers compared with the wide-type homozygotes carriers in T2DM patients was not statistically different in present study, so further researchs were needed by enlarging the sample PMID: 27576735
  17. ApoM rs805296 polymorphism may be a risk factor for developing coronary artery disease [meta-analysis] PMID: 26723879
  18. ApoM/HDL-C and apoM/apoA1 ratios could be used as indicators for identification of DN from healthy people and from T2DM patients. PMID: 28073663
  19. ApoM may be a biomarker of coronary artery disease. ApoM-855 T-->C substitution provides binding sites for AP-2alpha and reduces ApoM transcription activity PMID: 27841911
  20. Data indicate significant association between the single nucleotide polymorphism (SNP rs805296) of apolipoprotein M (ApoM) and the susceptibility to ankylosing spondylitis (AS) among Chinese Han population in Lanzhou. PMID: 27412944
  21. Serum apolipoprotein M was elevated in chronic obstructive pulmonary disease patients and increased gradually with chronic obstructive pulmonary disease severity. PMID: 27001252
  22. ApoM is excreted in the urine of children after cardiac surgery in children with acute kidney injury PMID: 26642098
  23. Hyperglycemia-induced downregulation of apolipoprotein M expression is not via the hexosamine pathway. PMID: 26377577
  24. ApoM is highly expressed in renal proximal tubule cells and is usually reabsorbed by giantin-associated proteins in a process, which is also affected in kidney disease. PMID: 25901639
  25. our findings present supportive evidence that ApoM is a regulator of human LRH-1 transcription, and further reveal the importance of ApoM as a critical regulator of bile acids metabolism PMID: 25987835
  26. -724 I/D polymorphism decreases the apoM promoter activity, down-regulates the apoM protein expression level, and increases the risk of myocardial infarction PMID: 25637426
  27. these findings demonstrated that apoM suppressed TNF-alpha-induced expression of ICAM-1 and VCAM-1 through inhibiting the activity of NF-kappaB. PMID: 26057873
  28. role of apoM in lipid metabolism and cardiometabolic diseases.(48-55) PMID: 25551802
  29. ApoM levels differ according to country of birth and are associated with IR and T2DM only in native-born Swedes, not Iraqis living in Sweden. PMID: 24984825
  30. Binary logistic regression analysis suggested that both apoM and apoAI mRNA may considered as independent risk factors for fetal macrosomia PMID: 25194312
  31. ApoM overexpression may have a potential role in improving insulin resistance in vivo and modulating apoM expression might be a future therapeutic strategy against insulin resistance in type 2 diabetes. PMID: 25144649
  32. Single nucleotide polymorphism in APOM is associated with lung cancer. PMID: 25187487
  33. the apolipoprotein M/HDL pathway may have a role in the pathogenesis of COPD and emphysema [meta-analysis] PMID: 23900982
  34. Decreased activities of apolipoprotein m promoter are associated with the susceptibility to coronary artery diseases. PMID: 24578614
  35. the functional single-nucleotide polymorphism APOM rs805297 G/T variant allele was associated with rheumatoid arthritis risk PMID: 23660425
  36. The apolipoprotein M rs805297 SNP is not associated with an increased risk for developing coronary artery disease, although it does independently correlate with dyslipidemia in Han Chinese individuals. PMID: 24341666
  37. Apolipoprotein M T-778C polymorphism is associated with serum lipid levels and the risk of coronary artery disease in the Chinese population. (Meta-analysis) PMID: 24040766
  38. Data indicate that palmitic acid induced suppression of apolipoprotein M (APOM) expression is mediated via the peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) pathway. PMID: 24508264
  39. The unique apoM/S1P-enriched plasma HDL may serve to deliver S1P to extrahepatic tissues for atheroprotection and may have other as yet unidentified functions. PMID: 24318881
  40. Apolipoprotein M as a chaperone for sphingosine-1-phosphate. [Review] PMID: 23652568
  41. Livers are involved in S1P dynamism, and it was suggested that apoM, produced from livers, increases circulating plasma S1P by augmenting the S1P output from livers and modifies extracellular S1P metabolism. PMID: 23664237
  42. Vascular endothelial growth factor downregulates apolipoprotein M expression PMID: 22877565
  43. Data support that the APOM C-1065A polymorphism is associated with increased risk for developing rheumatoid arthritis and dyslipidaemia in RA patients. PMID: 23190940
  44. The APOM gene rs707921 and rs707922 single nucleotide polymorphisms are associated with some serum lipid parameters. PMID: 23086303
  45. These data suggest that the plasma clearance of apoM, despite apoM primarily being associated with HDL, is influenced by LDL receptor-mediated clearance of apoB-containing particles. PMID: 22826357
  46. The present study demonstrated that apoM expression could be elevated by ABCA1 via the RXR/LXR pathway and LRH1 does not involve in the regulation of apoM by the activation of ABCA1, although the direct regulative pathway(s) between ABCA1 and apoM gene is still unknown yet. PMID: 22516753
  47. ApoM can bind oxidized phospholipids, increasing the antioxidant effect of HDL. PMID: 22204862
  48. Report plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. PMID: 21944699
  49. Single Nucleotide Polymorphism at the promoter region of the APOM gene is associated with rheumatoid arthritis. PMID: 21844665
  50. Raised ApoM levels in hepatitis B virus (HBV) infection may in turn suppress HBV replication PMID: 21875437
  51. Apolipoprotein M gene (APOM) polymorphism modifies metabolic and disease traits in type 2 diabetes. PMID: 21390319
  52. Results show that apoM, by delivering S1P to the S1P(1) receptor on endothelial cells, is a vasculoprotective constituent of HDL. PMID: 21606363
  53. Data demonstrate that ApoM T-778 C and C-1065A single-nucleotide polymorphisms were associated with increased risk of ischemic stroke in a Han Chinese population. PMID: 20872094
  54. the human apolipoprotein M gene is regulated in opposite ways by hepatocyte nuclear factor 1 and Jun transcription factors PMID: 21454713
  55. The PCSK9 pathway may contribute to plasma apoM regulation in humans. The influence of PCSK9 on circulating apoM appears to be modified by adiposity. PMID: 21122852
  56. hepatocellular carcinoma tissues had a reduced capacity to produce apoM than the adjacent non-tumor tissues PMID: 19796793
  57. ApoM metabolism is to a considerable extent independent of statin- and fibrate-affected pathways involved in cholesterol homeostasis PMID: 20828695
  58. ApoM is expressed in human colorectal tissues: comparison of expression in normal tissue/mucosa, adenocarcinoma (w/ or w/o lymphatic metastasis), polyps, and inflammatory mucosa. PMID: 20846402
  59. Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors. PMID: 20660599
  60. In subjects with critical limb ischemia (CLI), plasma concentrations of apoA-I, apoB and apoM were significantly lower than in control individuals, but only apoA-I was independently associated to CLI. PMID: 20080084
  61. ApoA-I, apoB and apoM levels were significantly lower in patients with abdominal aortic aneurysm than in the control individuals. PMID: 19932694
  62. ApoM may function catalytically at an intracellular site to transfer lipid onto pre beta HDL during or after their formation by ABCA1. PMID: 19767535
  63. HNF-1alpha is required for apoM expression in vivo, and heterozygous HNF-1alpha mutations lead to HNF-1alpha-dependent impairment of apoM expression. PMID: 14633861
  64. During human embryogenesis, apoM was mainly expressed in liver and kidney and little was found in small intestine PMID: 15147633
  65. we excluded APOM as a genetic determinant of Alzheimer disease in our large French case control population. PMID: 15172102
  66. results show that Apolipoprotein M (apoM) is positively related to leptin and negatively related to cholesterol in humans PMID: 15542348
  67. Results show that leptin does not significantly influence the expression of apolipoproteins AI, B and E in HepG2 cells, suggesting that leptin has a specific regulatory effect on hepatic apoM transcription and secretion in vitro. PMID: 15904876
  68. study provided the first evidence that SNP T-778C in the proximal promoter region of apoM was associated with the levels of plasma cholesterol & fasting plasma glucose & also conferred risk in development of type 2 diabetes in Han Chinese PMID: 16572495
  69. Results suggest that apoM is associated with a small heterogeneous subpopulation of HDL particles. PMID: 16682745
  70. We demonstrated the presence of five isoforms of apo M in LDL: three that are both N-glycosylated and sialylated, one that is N-glycosylated but not sialylated, and one that is neither N-glycosylated nor sialylated. PMID: 17022639
  71. Hepatic apoM expression is significantly influenced by the acute phase of hepatic ischemia-reperfusion injury. PMID: 17112825
  72. the binding of retinol and retinoic acid supports the hypothesis that apoM is a lipocalin. PMID: 17525477
  73. The apoM gene is a risk factor for genetic susceptibility to coronary artery disease and is also associated with total cholesterol levels in Han Chinese. PMID: 17674965
  74. results of the present study suggest that the APOM T-855C polymorphism carries an increased risk for coronary artery disease in this Chinese population PMID: 17973931
  75. APOM transcription is regulated by LRH-1 PMID: 17977826
  76. In the setting of low density lipoprotein receptor deficiency, apoM-Tg mice with approximately 2-fold increased plasma apoM concentrations developed smaller atherosclerotic lesions than controls. PMID: 18006500
  77. Apolipoprotein M is a negative acute response protein that decreases during infection and inflammation PMID: 18054359
  78. This strongly indicates that the signal peptide is indeed necessary for apoM's ability to associate with lipid. PMID: 18279674
  79. Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M PMID: 18381283
  80. The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma PMID: 18460466
  81. In conditional logistic regression analyses, apoM was not a predictor of CHD events. PMID: 18490703
  82. plasma apoM levels in hepatocellular carcinoma patients were significantly increased than those in the normal subjects, but lower than those in the chronic hepatitis and cirrhosis patients PMID: 18652652
  83. Data show that Allele C of SNP T-778C in Apolipoprotein M promoter may increase promoter activity and confer the risk susceptibility to the development of T1D. PMID: 19007767
  84. The findings suggest that ApoM could not be an independent risk factor but a biomarker of coronary artery disease. PMID: 19100249
  85. ApoM plays a part in lipoprotein metabolism; however, the biological impact of apoM in humans remains to be determined. PMID: 19200746
  86. Plasma apoM is reduced in metabolic syndrome PMID: 19539616
  87. Results describe the crystal structure of recombinant human apoM and show that apoM, although refolded from inclusion bodies, was in complex with fatty acids containing 14, 16 or 18 carbon atoms. PMID: 19733574

Show More

Hide All

Subcellular Location Secreted
Protein Families Calycin superfamily, Lipocalin family
Tissue Specificity Plasma protein. Expressed in liver and kidney.
Database Links

HGNC: 13916

OMIM: 606907

KEGG: hsa:55937

STRING: 9606.ENSP00000365081

UniGene: Hs.534468

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1